Danaher Receives Buy Rating from Matt Larew Amid Strong Financial Performance and Growth Potential

William Blair analyst Matt Larew has maintained their bullish stance on DHR stock, giving a Buy rating on April 17.

Matt Larew has given his Buy rating due to a combination of factors that highlight Danaher’s strong financial performance and growth potential. The company’s first-quarter results surpassed expectations, with total revenue slightly exceeding the previous year’s figures and beating both the firm’s and consensus estimates. Notably, the Cepheid respiratory segment significantly contributed to this revenue beat, while bioprocessing revenues showed robust growth, reflecting a positive trend in order volumes.
Furthermore, Danaher’s adjusted operating margin and EBITDA both exceeded projections, indicating efficient cost management and operational strength. The company’s adjusted EPS also outperformed expectations, reinforcing its financial health. Looking ahead, Danaher’s guidance for core revenue growth in 2025 remains optimistic, with anticipated growth in biotechnology and diagnostics segments, despite a challenging macroeconomic environment. These factors collectively underpin Matt Larew’s confidence in Danaher’s stock, leading to a Buy rating.

According to TipRanks, Larew is an analyst with an average return of -8.0% and a 38.46% success rate. Larew covers the Healthcare sector, focusing on stocks such as 908 Devices, Repligen, and Maravai Lifesciences Holdings.

In another report released on April 17, Leerink Partners also maintained a Buy rating on the stock with a $225.00 price target.